Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $10.50.
A number of research analysts recently weighed in on CATX shares. Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, September 15th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a research report on Friday, October 30th. Royal Bank Of Canada lowered Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $14.00 to $4.00 in a report on Monday, October 26th. Bank of America reduced their price target on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Friday, August 14th. Finally, BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a research note on Monday, October 26th.
Get Our Latest Stock Report on CATX
Institutional Investors Weigh In On Perspective Therapeutics
Large investors have recently made changes to their positions in the stock. Commodore Capital LP acquired a new position in Perspective Therapeutics during the first quarter worth approximately $26,424,000. Affinity Asset Advisors LLC raised its stake in Perspective Therapeutics by 954.9% in the first quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock valued at $13,196,000 after buying an additional 2,864,582 shares during the period. Avidity Partners Management LP lifted its position in shares of Perspective Therapeutics by 88.4% in the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after buying an additional 2,839,266 shares during the last quarter. Spruce Street Capital LP acquired a new stake in shares of Perspective Therapeutics in the first quarter valued at approximately $10,955,000. Finally, Yu Fan acquired a new stake in shares of Perspective Therapeutics in the first quarter valued at approximately $4,401,000. Institutional investors and hedge funds own 54.66% of the company’s stock.
Perspective Therapeutics Stock Up 6.5%
NYSEAMERICAN:CATX opened at $0.84 on Friday. Perspective Therapeutics has a twelve month low of $0.78 and a twelve month high of $6.16. The business has a 50 day moving average price of $2.34 and a two-hundred day moving average price of $3.49.
Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. The company had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.09 million. On average, research analysts expect that Perspective Therapeutics will post -0.98 EPS for the current year.
About Perspective Therapeutics
Perspective Therapeutics, Inc is a biotechnology company developing precision-targeted radiopharmaceutical treatments for cancer. The company’s platform is designed to deliver alpha-particle radiation directly to tumor cells by pairing radioactive isotopes with molecules that bind to specific cancer targets, with the goal of limiting damage to surrounding healthy tissue.
The company’s lead programs include VMT-α-NET, an investigational therapy directed at somatostatin receptor 2, a target commonly expressed by neuroendocrine tumors.
Read More
- Five stocks we like better than Perspective Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
